Skip Nav Destination
1-10 of 10
Biochem Soc Trans (2023) 51 (2): 597–612.
Published: 20 March 2023
... that blocking VEGF-A or CTLA4 alongside PD-L1 is effective in treating advanced HCC. Consequently, some immunotherapies may target and rely on oncofetal cells for clinical responsiveness. This understanding provides exciting opportunities to utilize oncofetal niche characteristics as biomarkers of immunotherapy...
Joy M. Burchell, Richard Beatson, Rosalind Graham, Joyce Taylor-Papadimitriou, Virginia Tajadura-Ortega
Biochem Soc Trans (2018) 46 (4): 779–788.
Published: 14 June 2018
... 2018 16 5 2018 © 2018 The Author(s) 2018 This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) . breast cancer glycosyltransferases immunotherapy lectins...
Biochem Soc Trans (2018) 46 (3): 659–668.
Published: 21 May 2018
... for preclinical studies and early trials can render the founding concept not always appropriate for proceeding to a larger definitive trial. Here, we summarize the attempts made, to date, to bring MUC1 into the world of cancer immunotherapy and discuss how research findings regarding MUC1 structure and function...
Biochem Soc Trans (2016) 44 (5): 1441–1454.
Published: 19 October 2016
..., or in conjunction with anti-angiogenic therapy or immunotherapy as a promising strategy for the treatment of human cancers. cancer immunotherapy signal transduction transforming growth factor-β tumor biology Transforming growth factor-β (TGF-β) is a ubiquitously expressed cytokine that mediates...
Biochem Soc Trans (2016) 44 (2): 349–355.
Published: 11 April 2016
...Lynsey M. Whilding; Sabari Vallath; John Maher Immunotherapy of cancer using chimeric antigen receptor (CAR) T-cells is a rapidly expanding field. CARs are fusion molecules that couple the binding of a tumour-associated cell surface target to the delivery of a tailored T-cell activating signal. Re...
Biochem Soc Trans (2016) 44 (2): 329–332.
Published: 11 April 2016
... immunotherapy oncology solid tumours Clinical trials have revealed spectacular efficacy in refractory leukaemia patients using anti-CD19 chimeric antigen receptor (CAR) adoptive T-cell therapy, with a 92% complete remission rate in 39 patients with acute lymphocytic leukaemia (ALL...
Arjan W. Griffioen, Andrea Weiss, Robert H. Berndsen, U. Kulsoom Abdul, Marije T. te Winkel, Patrycja Nowak-Sliwinska
Biochem Soc Trans (2014) 42 (6): 1608–1615.
Published: 17 November 2014
... chemotherapy combination therapy immunotherapy photodynamic therapy radiotherapy tyrosine kinase inhibitors Figure 1 Angiostatic combination therapy: different strategies, many challenges Angiogenesis inhibitors have firmly entered the current clinical practice for treatment...
Christine Galustian, Annapurna Vyakarnam, Oussama Elhage, Oliver Hickman, Prokar Dasgupta, Richard A. Smith
Biochem Soc Trans (2011) 39 (5): 1433–1436.
Published: 21 September 2011
... of incontinence and impotence can affect the quality of life of patients. Early intervention with localized immunotherapy represents a potential solution as lymphocyte infiltration does occur in prostate cancer lesions, and immunotherapy with dendritic cell vaccines can significantly increase survival in late...
Biochem Soc Trans (2005) 33 (4): 563–567.
Published: 01 August 2005
... The Biochemical Society 2005 1 To whom correspondence should be addressed (email firstname.lastname@example.org ). 28 3 2005 Alzheimer's disease amyloid β protein oligomer glutamatergic transmission hippocampus immunotherapy long-term potentiation Aβ (amyloid β) protein has been proposed...
Biochem Soc Trans (2002) 30 (4): 507–511.
Published: 01 August 2002
... pharmacokinetic properties to the demands of clinical applications. 1 To whom correspondence should be addressed (e-mail Thomas.Valerius@med3.imed.uni-erlangen.de ) 11 3 2002 © 2002 Biochemical Society 2002 immunotherapy Fc receptor recombinant ADCC, antibody-dependent cellular...